Literature DB >> 15760575

Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.

Paul Anderson1, James Louie, Anna Lau, Michael Broder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15760575     DOI： 10.1007/s11926-005-0002-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  25 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

3.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

4.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 5.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

6.  Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Authors:  Bernie Scallon; Ann Cai; Nancy Solowski; Amy Rosenberg; Xiao-Yu Song; David Shealy; Carrie Wagner
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

7.  Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Authors:  P Geborek; M Crnkic; I F Petersson; T Saxne
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 8.  A new era in rheumatoid arthritis treatment.

Authors:  Jill C Costello; Paul B Halverson
Journal:  WMJ       Date:  2003

9.  In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.

Authors:  H M Lorenz; C Antoni; T Valerius; R Repp; M Grünke; N Schwerdtner; H Nüsslein; J Woody; J R Kalden; B Manger
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

10.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01
View more
  3 in total

1.  MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity.

Authors:  Nobuo Sekiguchi; Chiyomi Kubo; Ayako Takahashi; Kumiko Muraoka; Akira Takeiri; Shunsuke Ito; Mariko Yano; Futa Mimoto; Atsuhiko Maeda; Yuki Iwayanagi; Tetsuya Wakabayashi; Shotaro Takata; Naoaki Murao; Shuichi Chiba; Masaki Ishigai
Journal:  MAbs       Date:  2018-10-01       Impact factor: 5.857

Review 2.  Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases.

Authors:  Flavio Caprioli; Roberta Caruso; Massimiliano Sarra; Francesco Pallone; Giovanni Monteleone
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis.

Authors:  Rebecca Anderson; Angels Franch; Margarida Castell; Francisco J Perez-Cano; Rolf Bräuer; Dirk Pohlers; Mieczyslaw Gajda; Alexandros P Siskos; Theodora Katsila; Constantin Tamvakopoulos; Una Rauchhaus; Steffen Panzner; Raimund W Kinne
Journal:  Arthritis Res Ther       Date:  2010-07-19       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.